These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 38189941)

  • 1. [New psychoactive substances in emergency medicine].
    Marinowitz R; Strube J; Schaper A
    Nervenarzt; 2024 Jan; 95(1):28-34. PubMed ID: 38189941
    [TBL] [Abstract][Full Text] [Related]  

  • 2. "Legal Highs"--An Emerging Epidemic of Novel Psychoactive Substances.
    Zawilska JB
    Int Rev Neurobiol; 2015; 120():273-300. PubMed ID: 26070762
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Growing Problem of New Psychoactive Substances (NPS).
    Madras BK
    Curr Top Behav Neurosci; 2017; 32():1-18. PubMed ID: 27571747
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Bonzai, lead and bath salt-poisoning with new and old drugs : Synthetic amphetamines, cathinones, cannabinoids and opioids-an overview].
    Strube J; Schaper A
    Med Klin Intensivmed Notfmed; 2019 Nov; 114(8):684-692. PubMed ID: 29404633
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A systematic review of the effects of novel psychoactive substances 'legal highs' on people with severe mental illness.
    Gray R; Bressington D; Hughes E; Ivanecka A
    J Psychiatr Ment Health Nurs; 2016 Jun; 23(5):267-81. PubMed ID: 27037639
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New Psychoactive Substances Toxicity: A Systematic Review of Acute and Chronic Psychiatric Effects.
    Taflaj B; La Maida N; Tittarelli R; Di Trana A; D'Acquarica I
    Int J Mol Sci; 2024 Aug; 25(17):. PubMed ID: 39273431
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New Psychoactive Substances (NPS) - a Challenge for the Addiction Treatment Services.
    Scherbaum N; Schifano F; Bonnet U
    Pharmacopsychiatry; 2017 May; 50(3):116-122. PubMed ID: 28444659
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New and Emerging Illicit Psychoactive Substances.
    Graddy R; Buresh ME; Rastegar DA
    Med Clin North Am; 2018 Jul; 102(4):697-714. PubMed ID: 29933824
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Examination of Synthetic Cannabinoid and Cathinone Use among a Drug-Using Offender Sample, 2013-2015.
    Smith KE; Bunting AM; Staton M; Walker R; Shalash S; Winston E; Pangburn K
    J Psychoactive Drugs; 2017; 49(5):436-445. PubMed ID: 28813207
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [New psychoactive substances and their prevalence in the Czech Republic].
    Mravčík V; Běláčková V; Grohmannová K; Zábranský T
    Cas Lek Cesk; 2015; 154(5):216-21. PubMed ID: 26612328
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Negative consequences of novel psychoactive substances use among the Polish users.
    Wieczorek Ł; Bujalski M; Dąbrowska K
    Psychiatr Pol; 2021 Apr; 55(2):447-469. PubMed ID: 34365491
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Motivations for new psychoactive substance use among regular psychostimulant users in Australia.
    Sutherland R; Bruno R; Peacock A; Lenton S; Matthews A; Salom C; Dietze P; Butler K; Burns L; Barratt MJ
    Int J Drug Policy; 2017 May; 43():23-32. PubMed ID: 28161577
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phantom menace: novel psychoactive substances and the UK Armed Forces.
    Hunter AH; Ayres T; Moreland N; Cox A
    J R Army Med Corps; 2018 Nov; 164(6):450-457. PubMed ID: 29934414
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reports of Adverse Events Associated with Use of Novel Psychoactive Substances, 2013-2016: A Review.
    Logan BK; Mohr ALA; Friscia M; Krotulski AJ; Papsun DM; Kacinko SL; Ropero-Miller JD; Huestis MA
    J Anal Toxicol; 2017 Sep; 41(7):573-610. PubMed ID: 28459969
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Death cases involving certain new psychoactive substances: A review of the literature.
    Kraemer M; Boehmer A; Madea B; Maas A
    Forensic Sci Int; 2019 May; 298():186-267. PubMed ID: 30925344
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel psychoactive substance poses a new challenge in the management of paranoid schizophrenia.
    Anderson C; Morrell C; Marchevsky D
    BMJ Case Rep; 2015 May; 2015():. PubMed ID: 25948854
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New Psychoactive Substances and Suicidality: A Systematic Review of the Current Literature.
    Chiappini S; Mosca A; Miuli A; Santovito MC; Orsolini L; Corkery JM; Guirguis A; Pettorruso M; Martinotti G; Di Giannantonio M; Schifano F
    Medicina (Kaunas); 2021 Jun; 57(6):. PubMed ID: 34204131
    [No Abstract]   [Full Text] [Related]  

  • 18. New/emerging psychoactive substances and associated psychopathological consequences.
    Schifano F; Napoletano F; Chiappini S; Guirguis A; Corkery JM; Bonaccorso S; Ricciardi A; Scherbaum N; Vento A
    Psychol Med; 2021 Jan; 51(1):30-42. PubMed ID: 31327332
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel psychoactive substances (designer drugs): overview and pharmacology of modulators of monoamine signaling.
    Liechti M
    Swiss Med Wkly; 2015; 145():w14043. PubMed ID: 25588018
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Scheduling of new psychoactive substance the Swiss way: A review and critical analysis.
    Grafinger KE; Bernhard W; Weinmann W
    Sci Justice; 2019 Jul; 59(4):459-466. PubMed ID: 31256819
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.